Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study
Efficacy of beta-blockers in heart failure according to left ventricular ejection fraction: An individual patient level analysis of double-blind randomised trials
Marked variation in the efficacy of beta-blockers across cardiovascular health: A Global systematic assessment of mortality, myocardial infarction and stroke
Does the risk for heart failure (HF) modulate the effectiveness of empagliflozin on HF hospitalisation or CV death in patients with type 2 diabetes without HF? Insights from EMPA-REG OUTCOME
Predicting right heart failure after implantation of continuous flow left ventricular assist devices (EUROMACS-RHF) score: analysis of the EUROMACS data